Laurus Labs Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Laurus Labs Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹205 of operating cash. Higher than 87% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹205Over the last 3 years, every ₹100 of reported profit came with ₹205 of operating cash.
Higher than 87% of Healthcare companies in India.
Self-Funding Ratio
1.2×Over the last 3 years its own operating cash covered its investment spending (capex) 1.2 times.
Lower than 56% of Healthcare companies in India.
Cash Locked Ratio
₹43For every ₹100 of sales, ₹43 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹39 tied up three years earlier.
More money tied up than 83% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
₹14Sales grew 12% in 3 years; of every extra ₹100 of sales, ₹14 became extra profit.
Lower than 58% of Healthcare companies in India.
Asset Productivity Ratio
+12% / +37%In 3 years sales changed by +12% while total assets changed by +37%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.9×Debt due within a year is covered 0.9 times by its yearly operating cash.
Lower than 55% of Healthcare companies in India.
Cash Cushion Ratio
−2%Debt, after subtracting cash, equals 2% of its market value (net debt).
Lower than 52% of Healthcare companies in India.
Tangible Assets Ratio
97%Of every ₹100 the company owns, ₹97 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 52% of Healthcare companies in India.
Tangible Net Worth Ratio
95%Of every ₹100 of net worth, ₹95 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 50% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Laurus Labs Limited owes ₹0.48 for every ₹1 it owns. Net profit rose 148% in the year to Mar 2026, and grew 4% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
97.4Investors pay ₹97.4 for every ₹1 of Laurus Labs Limited's yearly profit, higher than 91% of Healthcare companies in India.
P/B ratio
20.08The share price is 20.08 times Laurus Labs Limited's book value per share, higher than 98% of Healthcare companies in India.
Market cap
₹106,442 CrThe total market value of all of Laurus Labs Limited's shares at today's price (share price × number of shares), larger than 96% of Healthcare companies in India. PosiCap size class: Tito Cap.
Net worth (book value)
₹5,300 CrWhat Laurus Labs Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹98.09Net worth divided by the number of shares. The share price of ₹1,970 is 20.1 times this, which is the P/B above.
Return on equity (ROE)
20.6%Laurus Labs Limited earned 20.6% on its shareholders' money over the last year, higher than 82% of Healthcare companies in India.
Owes vs Owns
0.48×Laurus Labs Limited owes ₹0.48 for every ₹1 it owns (low), higher than 80% of Healthcare companies in India.
Dividend yield
0.12%Laurus Labs Limited pays 0.12% of its share price as dividends a year, lower than 84% of dividend-paying Healthcare companies in India.
Revenue growth
+22%Revenue rose 22% in the year to Mar 2026, and grew 4% a year on average over 3 years.
Profit growth
+148%Net profit rose 148% in the year to Mar 2026, and grew 4% a year on average over 3 years.
Profit margin
13.2%Laurus Labs Limited keeps ₹13 of every ₹100 of revenue as net profit.
Cash quality
1.8×Cash from Laurus Labs Limited's business was 1.8× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
8.1×Laurus Labs Limited's operating profit covered its interest costs 8.1 times in the year to Mar 2026.
Cash vs debt
Net debtLaurus Labs Limited had ₹2,406 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Laurus Labs Limited's P/E ratio?
Investors pay ₹97.4 for every ₹1 of Laurus Labs Limited's yearly profit, higher than 91% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Laurus Labs Limited: ₹106,442 Cr ÷ ₹5,300 Cr (31 Mar 2026) = 20.1.
What is Laurus Labs Limited's return on equity?
Laurus Labs Limited earned 20.6% on its shareholders' money over the last year, higher than 82% of Healthcare companies in India.
How much does Laurus Labs Limited owe compared with what it owns?
Laurus Labs Limited owes ₹0.48 for every ₹1 it owns (low), higher than 80% of Healthcare companies in India.
Does Laurus Labs Limited pay a dividend?
Yes. Laurus Labs Limited pays 0.12% of its share price as dividends a year, lower than 84% of dividend-paying Healthcare companies in India.
Is Laurus Labs Limited's revenue growing?
Revenue rose 22% in the year to Mar 2026, and grew 4% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.